← Back
December, 05th | 14:27 - 14:30
KAISER PETER
Add to calendar
A pulsar phase 3 trial post-hoc analysis: evaluating the timing and magnitude of control of disease activity with aflibercept 8 mg and faricimab, applying similar disease activity criteria across different pivotal phase 3 trials for NAMD